JP2014509325A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509325A5
JP2014509325A5 JP2013555876A JP2013555876A JP2014509325A5 JP 2014509325 A5 JP2014509325 A5 JP 2014509325A5 JP 2013555876 A JP2013555876 A JP 2013555876A JP 2013555876 A JP2013555876 A JP 2013555876A JP 2014509325 A5 JP2014509325 A5 JP 2014509325A5
Authority
JP
Japan
Prior art keywords
monovalent antibody
antibody according
seq
set forth
monovalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013555876A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014509325A (ja
JP6215056B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/053539 external-priority patent/WO2012117067A1/en
Publication of JP2014509325A publication Critical patent/JP2014509325A/ja
Publication of JP2014509325A5 publication Critical patent/JP2014509325A5/ja
Application granted granted Critical
Publication of JP6215056B2 publication Critical patent/JP6215056B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013555876A 2011-03-01 2012-03-01 拮抗性dr3リガンド Expired - Fee Related JP6215056B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11156416 2011-03-01
EP11156416.7 2011-03-01
US201161448827P 2011-03-03 2011-03-03
US61/448,827 2011-03-03
PCT/EP2012/053539 WO2012117067A1 (en) 2011-03-01 2012-03-01 Antagonistic dr3 ligands

Publications (3)

Publication Number Publication Date
JP2014509325A JP2014509325A (ja) 2014-04-17
JP2014509325A5 true JP2014509325A5 (cg-RX-API-DMAC7.html) 2015-04-23
JP6215056B2 JP6215056B2 (ja) 2017-10-18

Family

ID=44210048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013555876A Expired - Fee Related JP6215056B2 (ja) 2011-03-01 2012-03-01 拮抗性dr3リガンド

Country Status (12)

Country Link
US (4) US9737612B2 (cg-RX-API-DMAC7.html)
EP (1) EP2681237A1 (cg-RX-API-DMAC7.html)
JP (1) JP6215056B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140043720A (cg-RX-API-DMAC7.html)
CN (1) CN103517918A (cg-RX-API-DMAC7.html)
BR (1) BR112013022052A2 (cg-RX-API-DMAC7.html)
CA (1) CA2828464A1 (cg-RX-API-DMAC7.html)
IL (1) IL227535A0 (cg-RX-API-DMAC7.html)
MX (1) MX2013009859A (cg-RX-API-DMAC7.html)
RU (1) RU2013141079A (cg-RX-API-DMAC7.html)
WO (1) WO2012117067A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201306110B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140287952A1 (en) * 2013-03-15 2014-09-25 Alderbio Holdings Llc Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
WO2015036553A1 (en) 2013-09-16 2015-03-19 Novo Nordisk Health Care Ag Thiol functionalized polymers
CA2924520C (en) * 2013-11-01 2023-09-26 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
AU2015242752A1 (en) * 2014-04-04 2016-10-20 Kyowa Hakko Kirin Co., Ltd. Anti-death receptor 3 (DR3) antagonistic antibodies with reduced agonistic activity
EP3137495A4 (en) * 2014-04-28 2017-11-15 The National Institute for Biotechnology in the Negev, Ltd. Variants of dr3 and use thereof
EP3572502B1 (en) * 2017-01-20 2023-01-11 Kyoto University Method for producing cd8alpha +beta + cytotoxic t cells
EP3860653A1 (en) 2018-10-05 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
CN111808183B (zh) * 2020-07-25 2022-07-08 北京吉尔麦迪生物医药科技有限公司 一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白
EP4507779A1 (en) 2022-04-14 2025-02-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
JP7849919B2 (ja) * 2022-06-17 2026-04-22 セレクシン インコーポレイテッド ヒトdr3に特異的に結合する抗体及びその用途
CN116223818B (zh) * 2023-05-09 2023-07-21 四川大学华西医院 Dr3蛋白检测试剂在制备筛查aecopd的试剂盒的用途及筛查aecopd的试剂盒
CN116514983B (zh) * 2023-06-02 2025-05-23 安徽金百奥生物科技有限公司 一种靶向dr3胞外域的纳米抗体及其应用
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use
GB202315963D0 (en) 2023-10-18 2023-11-29 Cancer Research Tech Ltd Binding molecules
AU2025213136A1 (en) 2024-01-24 2026-07-16 Shattuck Labs, Inc. Antibodies that bind tnfrsf25

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
BR9910568A (pt) 1998-04-30 2001-09-11 Tanox Inc Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos
FR2780062B1 (fr) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
AU4478200A (en) 1999-04-22 2000-11-10 Human Genome Sciences, Inc. Death domain containing receptors
AU784504B2 (en) * 1999-11-19 2006-04-13 Thomas V. Tittle TR3-specific binding agents and methods for their use
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
EP1263788A2 (en) 2000-02-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
WO2002040680A2 (en) 2000-11-17 2002-05-23 The Burnham Institute Death domain proteins
PL366469A1 (en) 2001-04-05 2005-02-07 Immuno-Biological Laboratories Co, Ltd. Anti-osteopontin antibody and use thereof
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
KR100499989B1 (ko) 2002-12-27 2005-07-07 네오바이오다임 주식회사 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법
US20090317388A1 (en) * 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
DK1919954T3 (en) * 2005-08-30 2017-01-30 Univ Miami Immune modulating tumor necrosis factor receptor (TNFR25) - agonists, antagonists and immunotoxins
US20110195048A1 (en) 2008-10-08 2011-08-11 Podack Eckhard R Regulation of lymphocytes and uses therefor
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3

Similar Documents

Publication Publication Date Title
RU2013141079A (ru) Антагонические лиганды dr3
US11844814B2 (en) Methods for expansion or depletion of T-regulatory cells
US20140213772A1 (en) Cross-over dual variable domain immunoglobulin constructs
IL274595B2 (en) Antibodies specific to beta-tgf
HRP20211948T1 (hr) Djelatna sredstva koja se vežu na tigit i njihove uporabe
JP2017502667A5 (cg-RX-API-DMAC7.html)
JP2016509009A5 (cg-RX-API-DMAC7.html)
JP2012524071A5 (cg-RX-API-DMAC7.html)
JP2015502138A5 (cg-RX-API-DMAC7.html)
AU2013343556B2 (en) Modulation of monocytes, or precursors thereof, differentiation
JP2012254092A5 (cg-RX-API-DMAC7.html)
JP2016509582A (ja) 抗ヒトb7−h4抗体およびその使用
JP2019516350A (ja) キメラ抗原及びt細胞受容体、並びに使用方法
CN103145841A (zh) Il-12/p40结合蛋白
US20200377608A1 (en) Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody
JP2012070740A5 (cg-RX-API-DMAC7.html)
JP2011528720A5 (cg-RX-API-DMAC7.html)
JP2017500057A5 (cg-RX-API-DMAC7.html)
US20140213771A1 (en) Multi-specific binding proteins
JP2010527939A5 (cg-RX-API-DMAC7.html)
PE20120835A1 (es) Anticuerpos anti-tnf-alfa y sus usos
EP4196227A2 (en) Antibodies against ilt2 and use thereof
RU2013139480A (ru) Гуманизированные антитела против tnfa
JP2022535538A (ja) 抗cd137l抗体及びそれらの使用方法
Kesselring et al. The number of CD161 positive Th17 cells are decreased in head and neck cancer patients